Insulin

Pharma

Egypt: the quest to become an API hub

We saw in our recent articles that supply chain disruptions force countries to redefine their sovereignty policies in pharma. Policies have paved the way for local and global players to establish partnerships, such as Vision 2030 in Saudi Arabia. Last […]

Pharma

Insulin supply and localization of production: Malaysia’s case.

103 years after its discovery, insulin is reinventing itself: from pricing readjustments in major markets to the increasing usage of biosimilars. Historic players like Novo Nordisk and Eli Lilly seek growth outside insulin, with successes notably in obesity management drugs

Scroll to Top
WordPress Cookie Notice by Real Cookie Banner